{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T11:35:33Z","timestamp":1777203333487,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09450"],"award-info":[{"award-number":["20K09450"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.afos.2023.11.002","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T05:44:16Z","timestamp":1703137456000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8075-8319","authenticated-orcid":false,"given":"Shun","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-675X","authenticated-orcid":false,"given":"Yuji","family":"Kasukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-8929","authenticated-orcid":false,"given":"Koji","family":"Nozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsuchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-4239","authenticated-orcid":false,"given":"Kazunobu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihito","family":"Kasama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Harata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5175-3350","authenticated-orcid":false,"given":"Naohisa","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2023.11.002_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.ki.5002343","article-title":"Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes","volume":"72","author":"Levey","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2023.11.002_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2023.11.002_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115963","article-title":"Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels","volume":"148","author":"Metzger","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.afos.2023.11.002_bib7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","article-title":"Diseases of the parathyroid gland in chronic kidney disease","volume":"15","author":"Komaba","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.afos.2023.11.002_bib9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ki.1993.64","article-title":"The spectrum of bone disease in end-stage renal failure--an evolving disorder","volume":"43","author":"Sherrard","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.afos.2023.11.002_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.afos.2023.11.002_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"32","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.afos.2023.11.002_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2369-15-81","article-title":"Comparison of AMG 416 and cinacalcet in rodent models of uremia","volume":"15","author":"Walter","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.afos.2023.11.002_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116340","article-title":"Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease","volume":"157","author":"Swallow","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib18","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.afos.2021.11.001","article-title":"Analysis of bone in adenine-induced chronic kidney disease model rats","volume":"7","author":"Saito","year":"2021","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.afos.2023.11.002_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000183992","article-title":"Animal model of adenine-induced chronic renal failure in rats","volume":"44","author":"Yokozawa","year":"1986","journal-title":"Nephron"},{"key":"10.1016\/j.afos.2023.11.002_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00774-020-01184-0","article-title":"Teriparatide and exercise improve bone, skeletal muscle, and fat parameters in ovariectomized and tail-suspended rats","volume":"39","author":"Sato","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00774-021-01289-0","article-title":"Effects of teriparatide and low-intensity aerobic exercise on osteopenia in type 2 diabetes mellitus rats","volume":"40","author":"Abe","year":"2022","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2023.11.002_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bone.2007.08.041","article-title":"Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats","volume":"42","author":"Nozaka","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00774-019-01045-5","article-title":"Effects of bazedoxifene and low-intensity aerobic exercise on bone and fat parameters in ovariectomized rats","volume":"38","author":"Yuasa","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00774-018-0941-0","article-title":"Impact of vitamin C on teriparatide treatment in the improvement of bone mineral density, strength, and quality in vitamin C-deficient rats","volume":"37","author":"Miyakoshi","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jbmr.2539","article-title":"Establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones","volume":"30","author":"Jepsen","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2023.11.002_bib29","first-page":"457","article-title":"Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy","volume":"22","author":"Kasukawa","year":"2004","journal-title":"J Orthop Res"},{"key":"10.1016\/j.afos.2023.11.002_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.afos.2023.11.002_bib31","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bone.2019.05.002","article-title":"Time course of rapid bone loss and cortical porosity formation observed by longitudinal \u03bcCT in a rat model of CKD","volume":"125","author":"McNerny","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib33","first-page":"210","article-title":"Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review","volume":"6","author":"Bolasco","year":"2009","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.afos.2023.11.002_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2023.11.002_bib35","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","article-title":"Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia","volume":"28","author":"Ota","year":"2017","journal-title":"Osteoporos Int"},{"issue":"Suppl","key":"10.1016\/j.afos.2023.11.002_bib36","first-page":"S50","article-title":"Skeletal resistance to parathyroid hormone as a background abnormality in uremia","volume":"8","author":"Fukagawa","year":"2003","journal-title":"Nephrology"},{"key":"10.1016\/j.afos.2023.11.002_bib37","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/sj.ki.5001600","article-title":"Insufficiency of PTH action on bone in uremia","volume":"102","author":"Iwasaki","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.afos.2023.11.002_bib38","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/ki.1995.248","article-title":"Parathyroidectomy does not prevent the renal PTH\/PTHrP receptor down-regulation in uremic rats","volume":"47","author":"Ure\u00f1a","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","article-title":"Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report","volume":"65","author":"Palcu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.afos.2023.11.002_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.afos.2023.11.002_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.21037\/atm.2019.06.44","article-title":"Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats","volume":"7","author":"Ni","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.afos.2023.11.002_bib42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.bone.2006.06.010","article-title":"Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells","volume":"39","author":"Rickard","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib43","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.kint.2018.12.015","article-title":"Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration","volume":"95","author":"D\u00edaz-Tocados","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.afos.2023.11.002_bib44","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bone.2011.03.672","article-title":"Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease","volume":"48","author":"Iwasaki","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bone.2013.07.037","article-title":"Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease","volume":"57","author":"Iwasaki","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.11.002_bib46","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s00198-010-1454-4","article-title":"Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys","volume":"22","author":"Saito","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2023.11.002_bib47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/jbmr.4574","article-title":"Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease","volume":"37","author":"Damrath","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525523000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525523000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:35:20Z","timestamp":1762500920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525523000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2405525523000705"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2023.11.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2023.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}